Drug Profile

Research programme: CAR-T cell therapies - Nona Biosciences/Umoja Biopharma

Alternative Names: In vivo CAR-T cell therapies - Nona Biosciences/Umoja Biopharma

Latest Information Update: 11 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nona Biosciences; Umoja Biopharma
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

05 Nov 2025 Nona Bioscience and Umoja Biopharma expands partnership to create multiple in vivo CAR-T cell therapies for Cancer and Autoimmune disorders
12 Sep 2024 Nona Bioscience and Umoja Biopharma agree to co-develop CAR-T cell therapies for cancer and autoimmune disorders
12 Sep 2024 Early research in Autoimmune disorders in USA (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com